43 related articles for article (PubMed ID: 8956341)
1. Is the One-Compartment Model with First Order Absorption a Useful Approximation?
Weiss M
Pharm Res; 2023 Sep; 40(9):2147-2153. PubMed ID: 37594592
[TBL] [Abstract][Full Text] [Related]
2. Multiple peaking phenomena in pharmacokinetic disposition.
Davies NM; Takemoto JK; Brocks DR; Yáñez JA
Clin Pharmacokinet; 2010 Jun; 49(6):351-77. PubMed ID: 20481648
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
Jantratid E; Prakongpan S; Amidon GL; Dressman JB
Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
[TBL] [Abstract][Full Text] [Related]
4. A modified two-portion absorption model to describe double-peak absorption profiles of ranitidine.
Yin OQ; Tomlinson B; Chow AH; Chow MS
Clin Pharmacokinet; 2003; 42(2):179-92. PubMed ID: 12537516
[TBL] [Abstract][Full Text] [Related]
5. Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine.
Richards DA
J Clin Gastroenterol; 1983; 5 Suppl 1():81-90. PubMed ID: 6317740
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
Hatlebakk JG; Berstad A
Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
[TBL] [Abstract][Full Text] [Related]
7. Applications and simulations of a discontinuous oral absorption pharmacokinetic model.
Witcher JW; Boudinot FD
Pharm Res; 1996 Nov; 13(11):1720-4. PubMed ID: 8956341
[TBL] [Abstract][Full Text] [Related]
8. Use of a pharmacokinetic model incorporating discontinuous gastrointestinal absorption to examine the occurrence of double peaks in oral concentration-time profiles.
Suttle AB; Pollack GM; Brouwer KL
Pharm Res; 1992 Mar; 9(3):350-6. PubMed ID: 1614968
[TBL] [Abstract][Full Text] [Related]
9. Disposition of the anti-ulcer medications ranitidine, cimetidine, and omeprazole following administration of multiple doses to exercised Thoroughbred horses.
Knych HK; Stanley SD; Arthur RM; McKemie DS
J Vet Pharmacol Ther; 2017 Jan; 40(1):92-96. PubMed ID: 27292271
[TBL] [Abstract][Full Text] [Related]
10. A pharmacokinetic model for multiple sites discontinuous gastrointestinal absorption.
Plusquellec Y; Efthymiopoulos C; Duthil P; Houin G
Med Eng Phys; 1999 Oct; 21(8):525-32. PubMed ID: 10672785
[TBL] [Abstract][Full Text] [Related]
11. Variability in cimetidine absorption and plasma double peaks following oral administration in the fasted state in humans: correlation with antral gastric motility.
Takamatsu N; Welage LS; Hayashi Y; Yamamoto R; Barnett JL; Shah VP; Lesko LJ; Ramachandran C; Amidon GL
Eur J Pharm Biopharm; 2002 Jan; 53(1):37-47. PubMed ID: 11777751
[TBL] [Abstract][Full Text] [Related]
12. The effects of cigarette smoking on plasma concentrations of gastric antisecretory drugs.
Boyd EJ; Johnston DA; Wormsley KG; Jenner WN; Salanson X
Aliment Pharmacol Ther; 1987 Feb; 1(1):57-65. PubMed ID: 2979213
[TBL] [Abstract][Full Text] [Related]
13. Discontinuous oral absorption pharmacokinetic model and bioavailability of 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)uracil (L-FMAU) in rats.
Wright JD; Ma T; Chu CK; Boudinot FD
Biopharm Drug Dispos; 1996 Apr; 17(3):197-207. PubMed ID: 8983395
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of 1-(2-deoxy-2-fluoro-beta-L-arabinofuranosyl)-5-methyluracil (L-FMAU) in rats.
Wright JD; Ma T; Chu CK; Boudinot FD
Pharm Res; 1995 Sep; 12(9):1350-3. PubMed ID: 8570534
[TBL] [Abstract][Full Text] [Related]
15. Site-dependent small intestinal absorption of ranitidine.
Gramatté T; el Desoky E; Klotz U
Eur J Clin Pharmacol; 1994; 46(3):253-9. PubMed ID: 8070507
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
